Globus Medical Inc.'s stock plummeted 22.96% after its Q1 2025 earnings call, driven by a disappointing revenue performance, lowered EPS guidance, and ongoing integration challenges. The company reported a 1.4% year-over-year revenue decline to $598.1 million, missing expectations due to a 30.6% drop in enabling technology sales, supply chain disruptions from the NuVasive merger, and reimbursement headwinds in biologics and neuromonitoring. Non-GAAP EPS guidance was cut by $0.10 to $3.00-$3.30, reflecting costs from the early Nevro acquisition, which raised concerns about execution risks amids...
